CDK4/6 inhibitors in tablet form for hormone receptor-positive, HER2-negative breast cancer therapy. Applied in outpatient oncology settings by medical oncologists. Sourced from pharmaceutical suppliers, procured by hospital pharmacies for combination regimens with endocrine therapies.